Tag: AstraZeneca

Global Information, Inc. [JASDAQ 4171] Antibody drug conjugates are the emerging class of cancer targeting drugs which are built by attaching a small cytotoxic agent to an antibody via linker. The antibody targets the specific antigen which is presence on […]

Triple-negative breast cancer is characterized by the absence of progesterone and estrogen receptors. Triple-negative breast cancer does not respond to hormonal therapy and necessitates a combination of surgical procedures. The market for Triple-negative breast cancer treatment market is expected to […]

Metastatic Renal cell Carcinoma (mRCC) is expected to see a high growth during our forecast period. The market in the G7 countries is expected to reach USD 7.9 billion in 2030 with a CAGR of 7.5%. Primary drivers of this […]